Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenofibrate Combined With Ursodeoxycholic Acid in PBC Patients With an Incomplete Biochemical Response to UDCA
NCT02965911Phase 2Withdrawn
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Jan 2016
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of fenofibrate in primary biliary cholangitis (PBC) (2 arms), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoint: Alkaline Phosphatase at 12 months. Planned start Jan 2016; status: withdrawn.
02
Drugs
fenofibrate
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT02965911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02965911.